What Does "99% Purity by HPLC" Mean on a Peptide Certificate of Analysis — and What Has to Be Stated Beside It?

WARNING: LABORATORY RESEARCH USE ONLY. This material is synthesized and distributed strictly for B2B development, laboratory research, and analytical studies. It is not a drug, dietary supplement, or cosmetic. Under no circumstances is this chemical compound intended for human or veterinary diagnostic or therapeutic application. All research must be conducted by qualified laboratory personnel using appropriate safety controls.

Last reviewed: 2026-08-15 · Research use only.

"≥99% purity by HPLC" is the single most repeated sentence in the research-peptide supply market. It appears, in nearly identical wording, on the product pages of most vendors in the category. Taken on its own it is close to uninformative — not because it is usually false, but because a chromatographic purity figure is a measurement result, and a measurement result without its method is not interpretable. The same vial, analysed on two defensible methods, can legitimately produce two different numbers.

This page is about the second half of the statement: what has to appear beside the percentage before a receiving laboratory can do anything with it. It covers how the number is calculated, the parameters that determine its value, the specific reason area percent is not mass percent, and the impurity classes a chromatographic purity assay does not see at all.

It is written for a procurement reviewer or analytical chemist qualifying an incoming reagent. No compound-specific chemistry is restated here — for that, see the full Retatrutide chemical reference.

1. What the Number Is: Area Normalization

A chromatographic purity figure for a synthetic peptide is almost always an area percent obtained by area normalization: the target peak's area expressed as a fraction of the total integrated peak area in the chromatogram.

The United States Pharmacopeia describes the calculation in general chapter <621> Chromatography, under "Normalization procedure." Its formulation is worth reading closely, because two qualifying clauses in it are almost always dropped when the number is quoted:

"Provided linearity of the peaks has been demonstrated, individual monographs may prescribe that the percentage content of a component … is calculated by determining the area of the corresponding peak as a percentage of the total area of all the peaks, excluding those due to solvents or reagents or arising from the mobile phase or the sample matrix, and those at or below the disregard limit or reporting threshold."

— USP General Chapter <621> Chromatography

Bachem, describing its own peptide quality control, states the practical form of the same calculation:

"Purity is typically assessed by UV detection at 210–220 nm, where the area of the main peak in relation to the total area of all peaks reflects the peptide purity."

— Bachem, Quality Control of Amino Acids & Peptides: A Guide

So the figure is a ratio of detector response, not a ratio of mass, and its denominator is whatever the integration software counted as a peak.

This wording is not USP-specific. The normalization procedure is pharmacopoeially harmonized: the identical sentence appears in the Japanese Pharmacopoeia's General Test 2.00 Chromatography (§5.3), which states on its face that it "is harmonized with the European Pharmacopoeia and the U. S. Pharmacopeia," and the corresponding European text is Ph. Eur. 2.2.46 Chromatographic separation techniques. One detail is worth knowing because it is recent: EDQM's own published comparison of the 10th and 11.6 editions of 2.2.46 records that the qualifier "provided linearity of the peaks has been demonstrated" was added in the harmonized revision, and that the system-sensitivity requirement was re-anchored from the disregard limit to the reporting threshold. The precondition in row 7 of §2 is therefore a current requirement, not a legacy formality.

The harmonized texts also fix the size of the excluded band: under the quantitative approach, a reporting threshold — "the limit above which a peak is reported" — is generally 0.05%.

1.1 What USP <621> is — and what it is not

Certificates of analysis in this market routinely print "USP <621>" in a Method column, including the certificate Boss BioTech USA publishes for lot 06242026. It is worth being precise about what that citation conveys.

<621> is a general-procedures chapter. In its own words it "describes general procedures, definitions, and calculations of common parameters and generally applicable requirements for system suitability." It defines the normalization calculation quoted above and sets system-suitability requirements — and it explicitly defers acceptance criteria to individual monographs: "When specific requirements are stated in the monograph, they supersede the requirements mentioned in this chapter."

Two consequences follow, and both cut against how the citation is commonly read:

• <621> is not a specification and not a certification. It does not state that any substance must be 98% or 99% pure. Naming it identifies the technique and the calculation convention; it does not establish conformance to anything.
• There is no USP monograph for a research-only compound like Retatrutide. The clause that would supply acceptance criteria has nothing to point at. Any specification on such a certificate is one the testing laboratory or the customer set, not a compendial limit.

Phrasings such as "USP <621> certified," "USP compliant," or "meets USP purity requirements" therefore misdescribe the document. The defensible phrasing is "by RP-HPLC, area normalization per the approach described in USP <621>."

2. The Minimum Interpretable Purity Statement

This is the practical core of the page. A purity percentage becomes an interpretable measurement when the following accompany it. For each row: what goes wrong when it is omitted, and the published authority that requires, defines, or demonstrates its relevance.

No page located during the research for this article publishes this parameter set. Vendor technical pages generally state the area-percent formula and stop; instrument-vendor and CRO pages publish real method parameters without explaining why their disclosure matters.

3. Why Area Percent Is Not Mass Percent

This is the point at which most published explanations stop at an assertion. There is a quantitative basis for it, and it is the most useful single fact on this page.

Area normalization implicitly assumes every species in the chromatogram produces the same detector response per unit mass. That assumption is not true for peptides, and it is not true even at 214 nm. Kuipers and Gruppen measured the contributions directly:

"The peptide bond has a molar extinction coefficient of 923 M⁻¹ cm⁻¹. Tryptophan has a molar extinction coefficient that is approximately 30 times higher than that of the peptide bond, whereas … phenylalanine, tyrosine, and histidine are approximately six times higher."

— Kuipers & Gruppen, Journal of Agricultural and Food Chemistry, 2007

The consequence for a purity assay is direct. Synthesis-related impurities in a peptide are frequently deletion sequences — the target chain missing one or more residues. If the missing residue is a tryptophan, that impurity's absorbance per molecule drops sharply relative to the parent, and area normalization under-reports it. If the impurity retains the aromatic residues but is otherwise truncated, the bias runs the other way.

ICH addresses exactly this in the current analytical-validation guideline:

"If the analyte has a different response from the reference material (e.g., a different specific UV absorbance), relative response factors should be calculated using the appropriate ratio of responses… If the relative response factor is outside the range 0.8–1.2, then a correction factor should be applied."

— ICH Q2(R2), Validation of Analytical Procedures, Annex 2, Table 3 (adopted 1 November 2023)

0.8–1.2 is a published, checkable threshold. It is a far more useful thing to ask a supplier about than the percentage itself: were response factors evaluated, and were any outside the ICH window corrected? A certificate that reports an uncorrected area percent has not answered it.

3.1 A worked illustration of the arithmetic

The figures below are round illustrative numbers chosen to show the calculation. They are not measured data and do not describe any Boss BioTech USA lot.

Suppose a vial has a gross weight of 100.0 mg, a net peptide content of 80%, and an HPLC purity of 99% by area:

The vial is truthfully described as "99% pure by HPLC," and slightly under four-fifths of what is in it is the target peptide. The 99% never described the vial; it described the peptide fraction of the vial. AAPPTEC states the distinction plainly:

"Purity is determined by HPLC and indicates the presence/absence of contaminating peptides with undesired sequences. Net peptide content only gives information on the percent of total peptide versus total non-peptide components independently of the presence of multiple peptides."

— AAPPTEC, Peptide Quality FAQ

4. What a Chromatographic Purity Figure Does Not Account For

A 214 nm RP-HPLC area percent quantifies peptide-related species. Several other components of a real vial are determined by entirely separate methods, and none of them appears in that percentage. A 2023 review authored by USP scientists sets out the full accounting:

"All detectable impurities (e.g., peptide related impurities, counter ion, water, residual solvents, non-combustible residues) are measured and subtracted from 100% to assign purity."

— Pharmaceutical Research, 2023 (open access)

Its method table assigns a distinct technique to each class:

The same review states the correction explicitly for water:

"Water corrected purity was calculated as purity × (100.0 − %water) ÷ 100."

Bachem makes the general point in one sentence: counterions, solvents and water "are not measured by the same methods used to determine the purity of the desired product."

4.1 Co-elution: the item a purity figure conceals rather than omits

Co-elution deserves separate emphasis. Everything else in the table above is absent from the percentage; a co-eluting impurity is counted as the product. An impurity not resolved from the target under the method as run is integrated into the target peak and inflates the reported purity. USP names the failure mode directly — gradient adjustments can lead "to the masking of peaks" — and the chromatographic literature treats freedom from co-elution as a precondition rather than an assumption: Stoll and co-workers state that "it is critically important to ensure that no impurities coelute with the target peptide."

The most useful published demonstration of the size of this effect comes from Waters, which ran UV and high-resolution MS detection on the same synthetic peptide samples and compared the purity each returned:

"The purity levels determined from MS and UV response are different due to co-eluting peptides only detected in the MS-based purity assessment. The reported optical purity for Eledoisin API was 94.7% while MS was 74.8%"

— Waters Corporation, Synthetic Peptide Characterization and Impurity Profiling Using a Compliance-Ready LC-HRMS Workflow, literature code 720006367EN, August 2018

A UV area percent of 94.7% against 74.8% by MS on the same material is a ~20 percentage-point gap, and it is not a measurement error — both numbers are correct for what they measure. The UV figure is the honest output of a defensible method that could not separate the impurities present.

Two cautions on how to read that example. It is one published case on one peptide (Eledoisin), not a general correction factor, and no such general factor exists — do not carry the 20-point gap to any other compound. And it does not mean UV purity is worthless; it means a UV area percent is a statement about resolved species, and the resolution achieved is a property of rows 2–4 of the table in §2. This is precisely why an unstated method is not a documentation formality.

5. Applying the Test to Our Own Certificate

A page setting a documentation standard should be measured against it first.

Boss BioTech USA publishes the complete Certificate of Analysis for Retatrutide lot 06242026, issued by BTLabs, an independent contract analytical laboratory. Page 1 of that certificate reports an HPLC purity of the peptide assay of 99.8% against a printed specification of ≥98%, with the method column reading USP <621>.

Assessed against the ten items in §2, that certificate — like effectively every certificate of its type in this market — states one of them. It reports the orthogonal identity method (row 10): identity was established by FTIR under USP <197A>, not by mass spectrometry, and the certificate says so. It does not print the detection wavelength, the column, the mobile phase, the gradient, the temperature, the flow rate, the integration thresholds, whether linearity was demonstrated, whether response factors were applied, or whether the figure is corrected for water and counterion. Naming USP <621> identifies the calculation convention; it supplies none of those parameters.

The honest conclusion is the one this page's own argument requires: 99.8% is a real, externally generated result, and page 1 alone does not contain enough method information for a receiving laboratory to reproduce or fully interpret it. The certificate is paginated "page 1 of 2," and page 2 — the FTIR and HPLC instrument output — is where the chromatogram and its conditions live. That page has not been published here.

This is not a defect unique to one laboratory; it is the market-wide condition this page describes. The operative recommendation for any purchaser, including of our material, is the same: request the complete report by its report number, and ask for the chromatographic conditions and integration parameters if the summary page does not carry them. For Boss BioTech USA material the full two-page report is requested by report number through bossbiotechusa.com.

A B2B sourcing and supplier-verification guide is in development and will be linked here at launch.

6. Common Pitfalls When Comparing Purity Figures Between Suppliers

• Comparing percentages across suppliers who used different methods. Two vendors reporting 99.2% and 98.6% may not be reporting the same quantity. Without §2's parameters the comparison is not defined, and neither number is evidence about the other.
• Reading purity as an amount. Purity is a ratio within the peptide fraction; content is a mass. §3.1 shows how far apart they can sit on the same vial.
• Treating "99% purity, third-party tested" as a specification. It is the category's most common phrasing and carries no method, no lot, no laboratory, and no report number. A claim that cannot be traced to a document about a named batch is not a specification.
• Reading a general-chapter citation as certification. See §1.1.
• Assuming a single chromatographic method sees everything. §4. An orthogonal identity method is a separate requirement, not a redundancy.
• Accepting purity figures without a lot number. A purity result describes the sample tested. Generalised to "the product," it is no longer a measurement.

A note on published statistics in this area. During research for this page we encountered a widely circulated claim that independent testing between 2024 and early 2026 found roughly 73% of peptide samples showed purity discrepancies averaging 8.4 percentage points. We could not trace this to any dataset, laboratory, or publication, and we do not repeat it as fact. It is noted here only so readers who meet it elsewhere know it is, as far as we could establish, unsourced.

7. Frequently Asked Questions

Q: What does 99% purity mean for a research peptide? A: It normally means an area-percent result: the target peak accounted for 99% of the total integrated peak area in an RP-HPLC chromatogram, typically with UV detection near 210–220 nm. It is a ratio of detector response within the peptide-related fraction — not a statement of how much of the vial's mass is the target peptide, and not a confirmation of the peptide's identity.

Q: What is the difference between peptide content and peptide purity? A: They are different measurements. Per AAPPTEC, purity "indicates the presence/absence of contaminating peptides with undesired sequences," while net peptide content "gives information on the percent of total peptide versus total non-peptide components." A vial can be high-purity by peptide assay and still be largely non-peptide by mass, because purity is measured across the peptide fraction only.

Q: Why does purity percentage vary between suppliers? A: Partly because material differs, and partly because the measurement does. USP <621> lists mobile-phase composition, pH and ionic strength, flow rate, column dimensions and temperature, and stationary-phase particle and pore size among the factors affecting chromatographic behaviour, and warns that changing gradient conditions can cause coelution and the masking of peaks. Integration thresholds also change the denominator. Two defensible methods can return different area percentages for one sample.

Q: What is the best wavelength for measuring the absorbance of peptides during an HPLC run? A: Peptide purity is typically monitored near 210–220 nm, where the peptide bond itself absorbs (Bachem states 210–220 nm; the peptide bond's molar extinction coefficient at 214 nm is 923 M⁻¹ cm⁻¹). Detection at 280 nm responds only to tryptophan and tyrosine, with a smaller contribution from cystine — phenylalanine's contribution above 275 nm is negligible — so 280 nm will not see peptides lacking those residues.

Q: Does a 99% HPLC purity result confirm the peptide's identity? A: No. Chromatographic purity quantifies how much of the detected material is a single species; it does not establish which species. Identity requires an orthogonal technique — the USP-authored review cited below lists HPLC retention time, NMR, MS and chiral testing as the techniques typically used together, and Bachem states that molecular weight is determined by mass spectrometry.

Q: Can an HPLC purity figure overstate how pure a peptide is? A: Yes, when impurities co-elute with the target. An unresolved impurity is integrated into the main peak and counted as product. Waters published a direct comparison on synthetic peptide samples in which "the purity levels determined from MS and UV response are different due to co-eluting peptides only detected in the MS-based purity assessment," reporting 94.7% optical (UV) purity against 74.8% by MS for the same Eledoisin material. That is one published case on one peptide rather than a general correction factor, but it shows the mechanism is real and can be large.

Q: Should I be concerned about residual TFA in peptides? A: Trifluoroacetate is a common counterion from RP-HPLC purification, and it is worth noting that it does not appear in the HPLC purity percentage. It is determined by a separate assay; USP publishes a dedicated general chapter, <503.1> Trifluoroacetic Acid in Peptides, and a companion chapter <503> for acetic acid. If counterion identity or level matters for a given application, it must be requested as its own result.

Q: What method details should appear beside a purity figure on a Certificate of Analysis? A: At minimum: detection wavelength; column chemistry, dimensions, particle and pore size; mobile phase and modifier; the gradient program; column temperature and flow rate; the integration reporting threshold or disregard limit; whether linearity was demonstrated; whether response factors were applied; whether the figure is area percent or corrected for water and counterion; and the orthogonal method used to confirm identity. The full table with the reason for each is in §2 above.

8. Methodological and Scholarly References

1. United States Pharmacopeia, General Chapter <621> Chromatography — normalization procedure, system suitability, and factors affecting chromatographic behaviour. Harmonized text (PDF, official 1 December 2022) · current USP–NF record
2. ICH, Validation of Analytical Procedures Q2(R2), Final Version, adopted 1 November 2023 (error correction 30 November 2023) — Annex 2, Table 3, relative response factors and the 0.8–1.2 window; robustness parameters. ICH guideline PDF
3. Kuipers BJ, Gruppen H. Prediction of molar extinction coefficients of proteins and peptides using UV absorption of the constituent amino acids at 214 nm. Journal of Agricultural and Food Chemistry 2007;55(14):5445–5451. DOI 10.1021/jf070337l
4. Pharmaceutical Research 2023;40(6):1317–1328 (open access; USP-affiliated authors) — impurity accounting for synthetic peptide reference standards, water-corrected purity, and orthogonal identity confirmation. DOI 10.1007/s11095-023-03493-1 · PMC10338602
5. Stoll DR et al. Development of comprehensive two-dimensional liquid chromatography methods for synthetic peptide impurity analysis. Journal of Chromatography A 2023;1693 — column and mobile-phase selectivity screening; co-elution as a precondition. DOI 10.1016/j.chroma.2023.463874 and DOI 10.1016/j.chroma.2023.463873
6. Bachem, Quality Control of Amino Acids & Peptides: A Guide — UV detection at 210–220 nm, purity vs net peptide content, identity by mass spectrometry. bachem.com
7. AAPPTEC, Peptide Quality FAQ — purity vs net peptide content. peptide.com
8. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Science 1995;4:2411–2423 — 280 nm absorbance depends on Trp, Tyr and cystine; Phe's contribution above 275 nm is negligible.
9. Waters Corporation. Synthetic Peptide Characterization and Impurity Profiling Using a Compliance-Ready LC–HRMS Workflow. Ranbaduge N, Yu YQ. Literature code 720006367EN, August 2018 — UV- vs MS-derived purity on the same samples; co-eluting peptides detected only by MS. waters.com
10. EDQM, How should the test requirements be applied in related substances tests? — European Pharmacopoeia FAQ: the normalisation procedure, disregard limit and reporting threshold, and the 0.8–1.2 response-factor cases. faq.edqm.eu · definition of disregard limit / reporting threshold: faq.edqm.eu · EDQM comparison of Ph. Eur. 2.2.46 10th vs 11.6 editions (PDF): extranet.edqm.eu
11. Japanese Pharmacopoeia, General Test 2.00 Chromatography — harmonized with the European and U.S. Pharmacopoeias; §5.3 normalisation procedure, §6.4 reporting threshold. PMDA (PDF)
12. United States Pharmacopeia, General Chapters <503> Acetic Acid in Peptides and <503.1> Trifluoroacetic Acid in Peptides; and <1503> Quality Attributes of Synthetic Peptide Drug Substances (current version DOI 10.31003/USPNF_M12935_04_01). Cited here for existence, title and scope only — the chapter texts are subscription-gated and no content is attributed to them beyond their titles and public previews.

Related references: What is Retatrutide? (full chemical reference) · Certificate of Analysis data for Retatrutide lot 06242026 (HPLC purity, content assay, FTIR identity) · Do lyophilized research peptides need cold-chain shipping? · Retatrutide vs Tirzepatide vs Semaglutide: receptor-selectivity and chemical comparison · a B2B sourcing & verification guide is in development and will be linked here at launch.

Disclaimer: Boss BioTech USA distributes chemical compounds solely for laboratory research and analytical development. All products, including any discussed above, are not approved for human clinical use, diagnosis, prevention, treatment, or cure of any medical condition or disease. The purchaser assumes all risks associated with the handling, testing, and use of these materials.